Results Highlights:Revenue increased by 10.0% year-on-year to a record high of US$180.5 million, marking the fifth consecutive year of record-setting revenue performance.Sales volume hit a new high of 2.02 million units, representing a year-on-year increase of 16.2%.Gross profit rose by 7.0% to a record of US$122.4 million; profit attributable to owners of the Company rose by 5.5% to US$41.9 million.The Board has proposed a final cash dividend of HK12 cents per share, bringing the total cash dividend for the Year to HK27 cents per share alongside special dividend, representing a payout ratio of 68.4%.The Group remains in a robust financial position, with cash and bank balances of US$228.7 million at the end of the year for supporting potential acquisitions and the construction of new production facilities.Maintained revenue growth in major markets, with the Asia-Pacific market at 15.7%, the EMEA markets at 19.6%, and the US market at 37.0%.The Group actively leverages its sales network and expertise to assist high-quality medical device peers in selling their products globally, while diversifying its own product portfolio. One of the collaborative products has already been launched in Hong Kong, Malaysia, Germany, and Spain, and is progressively being rolled out to more markets in the APAC and EMEA regions.HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty (“PTA”) procedures, today announced its annual results for the year ended December 31, 2025 (“FY2025” or the “Year”). Despite significant external challenges, the Group demonstrated remarkable resilience, achieving historic highs in revenue, sales volume, and gross profit, along with improved net profit.During the Year, OrbusNeich’s investments to strengthen its global sales and marketing capabilities, as well as expand product offerings, continued to yield positive results. The Group achieved revenue growth for the fifth consecutive year, reaching a record high of US$180.5 million. Additionally, sales volume in FY2025 hit a new high of 2.02 million units, representing a year-on-year growth of 16.2%, which included an increase of 13.1% from proprietary products and 34.9% from third-party products. Gross profit, up by 7.0% year-on-year, reached a record high of approximately US$122.4 million, with profit attributable to owners of the Company increasing by 5.5% to $41.9 million, and basic earnings per share rising by 5.8% to US5.09 cents.As at December 31, 2025, the Group maintained a strong financial position with cash and bank balances amounting to US$228.7 million. Taking into consideration OrbusNeich’s solid operating performance, healthy cash reserves and future capital requirements, the Board has proposed a final cash dividend of HK12 cents per share (2024: HK10 cents per share), up by 20% year-on-year. Alongside the special cash dividend of HK15 cents per share paid during the Year to celebrate OrbusNeich’s 25th anniversary and express gratitude for shareholders’ long-standing support, the total cash dividend for FY2025 will be HK27 cents per share.Mr. David Chien, Chairman, Executive Director and Chief Executive Officer of OrbusNeich, said, “Building on 25 years of expertise, OrbusNeich achieved another strong performance in FY2025. Our commitment to product innovation and quality, and the establishment of dedicated local teams in diverse markets ensures that our products benefit vascular disease patients worldwide. During the Year, the Group advanced its strategy of building a comprehensive sales network while forging strategic collaborations, including providing commercialization support for Chinese medical device companies expanding overseas. Meanwhile, construction of our R&D and manufacturing base in Hangzhou is progressing steadily, reflecting our long-term growth ambitions.”Extensive Global Sales Network Fuels Strong Multi-Regional Revenue and Business GrowthOrbusNeich maintains an extensive sales network covering over 70 countries and regions through its 12 direct sales teams and distributor network, which includes the acquisition of a Taiwan-based distributor during the Year. During FY2025, the APAC region experienced a significant year-on-year increase in revenue of 15.7%, climbing to US$60.5 million, driven by strong performance in existing direct sales markets and the addition of the Taiwan market. Revenue growth in the EMEA region accelerated, rising by 19.6% to US$46.9 million, supported by rapid growth of over 20% in direct sales markets such as Germany, France, and Spain, along with substantial growth in distributor markets. As the impact of tariffs eased and product demand remained strong, revenue from the US market grew by 37.0% year-on-year, reaching US$21.2 million. Meanwhile, revenue from the Japan and PRC markets totaled US$32.3 million and US$17.8 million, respectively.In the second half of the year, the Group focused on strengthening its market presence in Europe and established a direct sales team in the Netherlands. The Group is establishing another direct sales team in Belgium in 2026, with the goal of achieving direct sales to local hospitals in both markets within the same year.OrbusNeich’s robust global sales network has attracted various manufacturers to collaborate with the Group on international market expansion. During the Year, the Group strengthened its partnership with SonoScape Medical Corp. by distributing their IVUS products across key APAC and European markets, including direct sales regions like Singapore, Malaysia, France, Germany, Spain, and Switzerland, as well as selected distributor markets in Europe. The IVUS products began generating sales in Hong Kong, Malaysia, Germany, and Spain by the end of FY2025.Strengthening a Diversified Portfolio via Parallel Global Registrations and Clinical TrialsAs at December 31, 2025, OrbusNeich owned more than 220 granted patents and published patent applications in key jurisdictions worldwide, as well as 35 PMDA-approved products, 42 CE-marked products, 20 FDA-cleared or approved products, and 24 NMPA-approved products.During the Year, the Group achieved progress in product registrations and clinical trials, including:Obtained PMDA approvals for Teleport Glide, Scoreflex QUAD, EZGuide LL (Large Lumen), Vascuaid and SIDEPASS, CE Marks for JADE PLUS and Teleport Glide, and NMPA approvals for the GuidingArk guiding catheter and Teleport XT;Submitted applications for FDA approval of Teleport Glide, PMDA approvals of Sapphire ULTRA and Sapphire NC ULTRA, and NMPA approvals of Scoreflex TRIO, Teleport Glide, Sapphire NC 24, Sapphire NC ULTRA, Sapphire ULTRA and JADE PLUS;Completed patient enrollment for the US clinical trial of Sapphire 3, with product registration expected to be submitted to the FDA in the first half of 2026;Completed patient enrolment of clinical registries for eucatech AG’s product eucaLimus and SUPPORT C, while patient enrollment for VITUS is still ongoing, with the goal of renewing CE Marks for these products under MDR by the end of 2027;Developing the proprietary coronary paclitaxel drug-coated balloon, Sapphire PTX, with a clinical trial application expected to be submitted to the PMDA in Q1 2026;Developing the peripheral scoring balloon, JADE Score, with registration applications expected to be submitted to the PMDA and the FDA in 2026.Optimizing Global Production Layout for Sustained Long-Term GrowthThe Group’s facilities in Shenzhen, the PRC; Hoevelaken, the Netherlands; and Weil am Rhein, Germany, achieved a combined annual production capacity of approximately 2.1 million units of balloons and stents as at December 31, 2025. To meet future production needs, construction of OrbusNeich’s largest R&D and manufacturing facility in Hangzhou, the PRC, is underway. Following the topping-out ceremony in the second half of 2025, marking the completion of construction of the main structure, renovation work has been ongoing since the end of 2025. The new facility is expected to commence operation in 2027, adding an annual production capacity of 2.4 million units.Mr. Chien concluded, “Looking ahead to 2026, OrbusNeich will continue leveraging its global platform to navigate ongoing external challenges. With the launch of new proprietary and eucatech AG products, rising third-party product sales, and the shift from distribution model to direct sales in certain markets, we expect steady revenue growth in the future. The Group will also explore potential downstream acquisitions in Europe to further consolidate our brand position. Going forward, we aim to sharpen our commercialization edge, maintain leadership in innovation and quality, and explore new business models to drive growth. Ultimately, these initiatives will reinforce our global competitiveness and further our founder, Mr. Teddy Chien’s vision of ‘benefitting humanity’ by improving patients’ quality of life worldwide.”About OrbusNeich Medical Group Holdings LimitedOrbusNeich is a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, our Group sells its products in more than 70 countries and regions worldwide. It is also actively expanding into structural heart disease. With an in-house R&D team boasting over 20 years of product development expertise, our Group has developed world-leading proprietary technologies.For more information, please visit the Group’s official website: https://orbusneich.com/.Media InquiriesStrategic Financial Relations LimitedAngelus LauTel: (852) 2864 4805Email: angelus.lau@sprg.com.hkDoris HoTel: (852) 2114 4916Email: doris.ho@sprg.com.hkBailey ZhouTel: (852) 2114 2825Email: bailey.zhou@sprg.com.hkWebsite: https://www.sprg.com.hk/OrbusNeich Medical Group Holdings Limited Maggie LauTel: (852) 3109 7234Email: mlau@orbusneich.comLucille Tsang Tel: (852) 3109 7292Email: ltsang@orbusneich.comWebsite: https://orbusneich.com/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績亮點：收入同比增長10.0%至1.80億美元，連續五年創新高。銷量破紀錄，達202萬件，同比增長16.2%。毛利上升7.0％至1.22億美元新高；公司擁有人應佔利潤增長5.5%至約4,190萬美元。董事會建議派發末期股息每股12港仙，連同特別股息，本年度現金股息總額達每股27港仙，派息比率為68.4％。財務狀況穩健，年末現金及銀行結餘為約2.29億美元，支持潛在收購及新生產設施建設。主要市場收入繼續增長，亞太地區市場增長15.7％，歐洲、中東及非洲市場增長19.6%，及美國市場增長37.0%。集團積極透過其銷售網絡及專業知識，協助優質醫療器械同業的產品邁向全球，同時豐富自身的產品組合。其中一款合作產品已於香港、馬來西亞、德國及西班牙上市，並正逐步推廣至亞太及歐洲、中東及非洲地區更多市場。香港, 2026年3月12日 - (亞太商訊 via SeaPRwire.com) - 專營經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）手術介入器械的全球醫療器械製造公司業聚醫療集團控股有限公司（「業聚醫療」或「集團」；股份代號：6929）今天宣佈截至2025年12月31日止年度（「2025財政年度」或「回顧年」）的全年業績。儘管外圍環境充滿挑戰，集團仍展現非凡韌性，收入、銷量及毛利齊創歷史新高，純利亦錄得增長。回顧年內，業聚醫療在強化全球銷售與營銷能力及擴大產品組合投資方面，繼續取得顯著成效。集團收入連續五年實現增長，達180.5百萬美元新高。2025財政年度銷量亦創新高，同比增長16.2%至202萬件，其中自有產品及第三方產品銷量分別增長13.1%及34.9%。毛利同比增長7.0％至122.4百萬美元，同創歷史高位；公司擁有人應佔利潤增長5.5%至41.9百萬美元。每股基本盈利上升5.8%至5.09美仙。於2025年12月31日，集團的財務狀況維持穩健，現金及銀行結餘達約228.7百萬美元。鑑於業聚醫療穩健的營運表現、充裕的現金儲備及考慮到未來資本需求，董事會建議派發末期現金股息每股12港仙（2024年：每股10港仙）。連同較早前為慶祝業聚醫療成立25周年及答謝股東長期支持而派發的每股15港仙特別現金股息，2025財政年度的現金股息總額為每股27港仙。業聚醫療董事長、執行董事兼首席執行官錢永勛先生表示：「業聚醫療憑藉過去25載建立的實力，於2025財政年度再創佳績。我們一直堅持產品創新與品質至上的承諾，並建立專業團隊紮根全球各主要市場，確保產品可惠及世界各地的血管疾病患者。本年度，集團持續擴展全球銷售網絡，同時推進多項策略性合作，包括為期望進軍海外市場的中國醫療器械企業提供商業化支持。同時，我們位於杭州的研發及生產基地建設進展順利，充分展現集團尋求長遠增長的決心。」銷售網絡遍及全球，推動多區域收入及業務強勁增長業聚醫療的龐大銷售網絡，是由12個直銷團隊（包括本年度收購的一家台灣分銷商）及分銷商網絡組成，遍及全球70多個國家和地區。2025財政年度，有賴現有直銷市場的強勁表現及台灣市場的額外貢獻，亞太地區收入同比大幅增長15.7%至60.5百萬美元；歐洲、中東及非洲地區方面，德國、法國及西班牙等直銷市場錄得逾20.0%的快速增長，分銷商市場亦增長顯著，帶動該區整體收入加速增長，上升19.6%至46.9百萬美元。而隨關稅影響緩解加上產品需求持續強勁，美國市場收入同比增長37.0%至21.2百萬美元。而日本及中國內地市場的收入分別為32.3及17.8百萬美元。下半年，集團重點強化歐洲市場佈局，在荷蘭建立了直銷團隊。2026年，集團正於比利時設立另一直銷團隊，以期在同年於兩地市場實現向醫院直銷。業聚醫療廣泛的全球銷售網絡吸引了眾多製造商攜手合作，共同拓展國際市場。本年度，集團深化與深圳開立生物醫療科技股份有限公司的合作，於多個亞太及歐洲主要市場分銷其血管內超聲（IVUS）產品，涵蓋新加坡、馬來西亞、法國、德國、西班牙、瑞士等直銷市場，以及歐洲數個選定的分銷市場。於2025財政年底前，該產品已於香港、馬來西亞、德國及西班牙市場實現銷售。全球註冊與臨床齊頭並進，強化多元創新產品組合截至2025年12月31日，業聚醫療在全球主要司法管轄區擁有超過220項授權專利及已公佈專利申請，包括35款獲PMDA批准產品、42款獲CE標誌產品、20款獲FDA許可產品及24款獲國家藥監局批准產品。本年度，集團在產品註冊及臨床試驗方面繼續取得進展，包括：Teleport Glide、Scoreflex QUAD、EZGuide LL（大管腔）、Vascuaid及SIDEPASS獲PMDA批准，JADE PLUS及Teleport Glide獲CE標誌，GuidingArk導引導管及Teleport XT獲國家藥監局批准；就Teleport Glide向FDA提交檢准申請、就Sapphire ULTRA及Sapphire NC ULTRA向PMDA提交批准申請；就Scoreflex TRIO、Teleport Glide、Sapphire NC 24、Sapphire NC ULTRA、Sapphire ULTRA及JADE PLUS向國家藥監局提交批准申請；完成Sapphire 3美國臨床試驗的病人入組工作，預計於2026年上半年向FDA提交產品註冊申請；完成eucatech AG旗下產品eucaLimus及SUPPORT C的臨床登記的病人入組，並進行VITUS的病人入組工作，目標於2027年底前取得MDR下的CE標誌認證；開發自有冠狀動脈紫杉醇藥物塗層球囊Sapphire PTX，預計於2026年第一季向PMDA提交臨床試驗申請；開發外周刻痕球囊JADE Score，預計於2026年向PMDA及FDA提交註冊申請。優化全球產能佈局，實現可持續的長遠增長集團位於中國深圳、荷蘭荷佛拉肯及德國萊茵河畔魏爾的生產設施，於2025年12月31日的球囊及支架年產能達約210萬件。為滿足未來生產需要，集團正於中國杭州興建旗下最大型的研發及生產設施。項目封頂儀式已於2025年下半年舉行，標誌該設施主體結構工程竣工，裝修工程亦於2025年底啟動。新設施預計於2027年投入營運，屆時將新增年產能240萬件。錢先生總結：「展望2026年，業聚醫療將繼續善用全球平台應對當前外圍挑戰。隨著自有新產品及eucatech AG產品推出、第三方產品銷量持續增長，以及部分市場由分銷轉向直銷模式，我們預期未來收入將穩步上升。集團亦將於歐洲物色潛在的下游收購目標，以進一步鞏固品牌地位。未來，我們將繼續強化商業化方面的競爭優勢，保持產品創新與卓越品質方面的領先地位，並積極探索新業務發展模式，以達致增長。這些舉措不僅能鞏固集團的全球競爭力，更將延續創始人錢學雄先生『造福人群』的初心與使命，為全球患者帶來更美好的生活。」關於業聚醫療集團控股有限公司業聚醫療是一家全球醫療器械製造公司，專門生產用於經皮冠狀動脈介入治療（PCI）及經皮腔內血管成形術（PTA）的介入器械。本集團總部位於中國香港，產品銷往全球超過70個國家和地區。集團亦積極將業務擴展至結構性心臟病領域。憑借擁有逾20年產品開發經驗的內部研發團隊，本集團已開發出世界領先的專有技術。如需瞭解詳情，請訪問集團官網：https://orbusneich.com/傳媒垂詢縱橫財經公關顧問有限公司劉若琪電話：(852) 2864 4805電郵：angelus.lau@sprg.com.hk 何田田電話：(852) 2114 4916電郵：doris.ho@sprg.com.hk周百霖電話：(852) 2114 2825電郵：bailey.zhou@sprg.com.hk 網站: www.sprg.com.hk業聚醫療集團控股有限公司劉慧菁電話：(852) 3109 7234電郵：mlau@orbusneich.com曾 璐電話：(852) 3109 7292電郵：ltsang@orbusneich.com網站: https://orbusneich.com/ Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – As the average age of the global population continues to rise, the Chinese Mainland is now home to the world’s largest number of seniors. Recognising this, the country’s 15th Five-Year Plan calls for proactive measures to address the challenges of an increasingly ageing population. The silver economy is set to be one of the vital engines for the mainland's next wave of economic growth.The Hong Kong Trade Development Council (HKTDC) has released a new consumer survey report, Chinese Mainland Silver Economy Opportunities, that details the strong spending power of the mainland’s affluent, middle-class senior consumers, as well as the vast untapped potential of this particular sector of society. With securing "happiness" and ensuring "quality" as their spending priorities, the survey shows that such consumers regard Hong Kong-made products as guaranteed to be authentic, while the city’s services sector is seen as professional and reliable. As a result, many of these consumers pronounce a willingness to pay a "Hong Kong premium".Believing that the continued expansion of the mainland's silver economy represents significant opportunities for Hong Kong businesses, Bruce Pang, HKTDC Director of Research, said: "Among other priorities, the 15th Five-Year Plan focuses on boosting domestic demand as a means of driving economic growth. Inevitably, this will create opportunities for Hong Kong companies looking to expand into the Chinese Mainland market.“By gaining a deeper understanding of the consumption patterns of mainland seniors, particularly those in the higher-spending middle-class and affluent segments, Hong Kong businesses will be able to effectively penetrate the domestic market."To gain a more in-depth understanding of the development opportunities in the country’s silver economy, HKTDC surveyed more than 2,000 middle-class/affluent senior consumers in various mainland cities last year. The broad cross-section of respondents included those in their 50s starting to plan their retirement, those entering retirement in their 60s, and the older post-retirement population (aged 70 and above). According to the survey’s findings, respondents' average monthly expenditure on daily consumer goods and services was approximately RMB7,000, rising to RMB8,000 for those in first-tier cities.Commenting on the findings of the survey, Wing Chu, the HKTDC’s Deputy Director of Research, who led the study, said: "Currently, the Chinese Mainland's silver economy is valued at about RMB7 trillion – some 6% of overall GDP. This is projected to surge to RMB30 trillion by 2035, indicating the segment’s huge development potential.“The survey also showed that more than half of such consumers had purchased Hong Kong products or services, consequently holding Hong Kong brands in particularly high regard. It was also notable that 78% of respondents were willing to pay a premium for Hong Kong-sourced products, while 84% were willing to do so in the case of the city’s services sector. Typically, respondents were willing to pay a 16.4% premium on products and 15.4% premium on services, with those in first-tier cities happy to pay an even higher percentage for many types of products and services.”Hong Kong brands enjoy stellar reputationOverall, many of the mainland’s senior consumers have a highly positive view of Hong Kong brands, with the city’s products celebrated for their quality and authenticity, and its services for their professionalism and reliability. On the product front, 61% of respondents had purchased Hong Kong products in the past year, including health foods (24%), luxury goods (18%) and beauty and personal care products (17%). In terms of future purchases, respondents expressed the greatest interest in Hong Kong health foods, leisure foods and beverages.Regarding the city’s services, 54% of senior respondents said they had utilised Hong Kong services in the past year, including beauty and personal care services (25%), travel to Hong Kong, Macao and Taiwan (22%) and financial and wealth management services (20%). Over the next 12 months, the most sought-after Hong Kong services were said to relate to health and wellness services, followed by beauty and personal care services.Digging deeper into the preferences of such consumers, HKTDC Economist Eric Chu said: "When choosing products and services, happiness is the priority for Chinese Mainland seniors, closely followed by value for money. With this in mind, Hong Kong businesses can leverage the silver economy by capitalising on the strong reputation and professional advantages of the city’s brands.“Specifically, they should consider expanding into the higher-spending first and second-tier cities, while targeting the younger segment of the senior population. Enhancing the offline experience and fostering word-of-mouth recommendations, alongside optimised promotional efforts, will also help Hong Kong businesses stand out in the mainland’s rapidly growing silver market.”Silver generation shaping a “blue ocean” of consumptionTaking a more in-depth look at the survey findings, 65% of respondents prioritised products or services that would enhance their leisure or bring them happiness, while 63% valued reasonable pricing and good value for money, and 62% focused more on the practicality and durability of the products or services on offer. Collectively, this indicates that mainland seniors are particularly concerned about their health and quality of life, while also valuing cost-effectiveness and functionality, marking them out as a notably mature and rational consumer group.In terms of product consumption, 23.3% of respondents most frequently purchased food and beverages, followed by home products (12.6%) and clothing (12.5%). In the case of services, 20.3% utilised body wellness services most often, followed by beauty and personal care services (16.7%) and leisure and entertainment services (13.1%).In addition, despite the popularity of online shopping across the mainland, the survey showed that physical stores remain the primary consumption channel for the more elderly demographic. For such consumers, offline experiences, in-person consultations and a sense of trust in products and services remain prime considerations.To help businesses capitalise on opportunities arising from the silver economy market, the HKTDC has incorporated various related elements into many of its exhibitions and forums. This allows relevant companies to showcase their products and technologies, while also giving them the opportunity to explore the latest industry developments through a series of related seminar programmes.Aligning with this approach, a thematic seminar on healthy ageing was held as part of the Asia Summit on Global Health, while the Rehabilitation and Elderly Care zone at the Hong Kong International Medical and Healthcare Fair featured the latest gerontechnology products. The Hong Kong Electronics Fair (Autumn Edition) also sought to showcase fitness and health products relevant to the senior market.In addition, the Hong Kong Toys & Games Fair, held in January this year, introduced a new “Happy Ageing” label for silver market products, making it easier for buyers to identify toys and related products designed specifically for older consumers. The Asia Toys & Games Forum, held during the fair, hosted a discussion by a number of international experts on the optimum design of toys for the elderly, while also offering many other insights into the silver-focused toy market.Looking ahead, the HKTDC will continue to provide comprehensive support to the business sector, enabling enterprises to further explore and develop opportunities in the growing silver economy market.ReferencesReport link: https://research.hktdc.com/en/article/MjI2ODIyMDg0NwHKTDC Research: http://research.hktdc.com/enPhoto download: https://bit.ly/4shpQjOHKTDC Director of Research Bruce Pang (centre), Deputy Director of Research Wing Chu (left) and Economist Eric Chu (right) presented key findings from the "Chinese Mainland Silver Economy Opportunities" consumer survey reportHKTDC Media Room: http://mediaroom.hktdc.com/enMedia enquiriesFor enquiries, please contact:Raconteur PR Agency:Betsy TseTel: (852) 9742 7338Email: betsytse@raconteur.hkMolisa LauTel: (852) 6187 7786Email: molisalau@raconteur.hkHKTDC Communication and Public Affairs Department:Clayton LauwTel: (852) 2584 4472Email: clayton.y.lauw@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shantou China, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) - From March 18 to 20, 2026, the 5th China Chaoshan International Textile and Garment Exhibition will be held at the Shantou International Convention & Exhibition Center, under the theme “Five Continents Gather in Chaoshan”.This year, the Exhibition has been fully upgraded in scale, covering over 150,000 square meters and featuring more than 100 product categories. It will bring together over 1,200 exhibitors showcasing more than 200,000 new products and bestsellers, and is expected to attract over 140,000 professional buyers seeking business opportunities.The buyers come from hundreds of cities and provinces across China, as well as more than 40 countries and regions overseas, encompassing Chinese and international purchasers, both online and offline buyers. The audience spans all channels, including e-commerce shelves, livestream e-commerce, cross-border platforms, ready-to-wear brands, private domain/group purchases, overseas trade, agents/distributors, brick-and-mortar chains, supermarkets/department stores, and well-known IPsThe appeal of the Exhibition lies in the quality and quantity of professional attendees. The 5th China Chaoshan International Textile and Garment Exhibition precisely matches the product categories of exhibitors with the needs of buyers, efficiently connecting partners and attracting the top procurement representatives across key channels within the industry, offering exhibitors unprecedented business opportunities.It brings together leading internet fashion brands and buyers, such as Bananain, Beneunder, NEIWAI, and Luckymeey, who drive online market growth and provide exhibitors with a golden channel for scalable exposure and precise user reach.Top KOLs, leading MCN (Multi-Channel Network) agencies, and livestreamers will unlock traffic potential, becoming a new engine for brands to amplify both awareness and sales.Leading lingerie retail chains integrate resources to efficiently meet the end-market procurement needs, building a stable, high-end channel network and providing brands with solid market penetration capabilities.Core regional agents and channel leaders in provincial and city-level markets cultivate local distribution networks and end-market operations, helping products achieve deeper market penetration and channel expansion.The Exhibition also gathers national-level chain supermarkets, high-end department store groups, and large shopping centers, providing large-scale physical venues that lay a solid foundation for offline retail partnerships.Mainstream cross-border platforms such as Amazon, eBay, SHEIN, and TEMU, along with major international and local e-commerce sellers, will participate, opening full-chain overseas opportunities for brands and helping enterprises enter the global textile and apparel consumer market.Representatives from leading e-commerce platforms, including Alibaba, POIZON, JD.com, Douyin, and VIP.com, will attend to connect with exhibitors, sharing insights on platform traffic and algorithm trends to drive online bestsellers and omni-channel growth.Top buyers from well-known lingerie brands will serve as partners guiding professional trends. Representatives from leading lingerie brands such as Aimer, Gujin, HODO, and FENTENG will be present, providing buyers with a fast-track to the full range of lingerie products.Top buyers from apparel brands bring mature brand matrices and customer bases, providing strategic channels to expand product reach and serve as partners in market breakthroughs and value enhancement.Invitations for professional buyers to the 5th China Chaoshan International Textile and Garment Exhibition are still ongoing, helping you explore more opportunities in the industry, secure real orders, and establish meaningful partnerships. We warmly invite industry friends to join us on-site and participate in this grand event!March 18 to March 20, 2026Shantou International Convention & Exhibition CenterWe sincerely invite you to attend and explore new opportunities in the industry.Media contactCompany Name: Shantou Zhongbo Exhibition Co., Ltd.Contact Person Name: James XiaoContact Person Title: General Manager AssistantOfficial Website: www.ctge.net/en/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 12, 2026 - (ACN Newswire via SeaPRwire.com) – Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Axonex Intelligence Limited (“AXONEX”) has entered into a joint venture agreement (the “JV Agreement”) with Synergy Technology Group Limited (“STG”) to establish Axonex Automation Limited (“JV company”), a new Hong Kong-based joint venture company focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.Under the JV Agreement, AXONEX will hold an 80% equity interest in Axonex Automation Limited, while STG will hold the remaining 20%. The joint venture will combine AXONEX’s operational resources and international business capabilities with STG’s proven technology in digital twins and drone flight control systems to drive scalable deployment in sectors such as infrastructure inspection, utilities, smart cities, and industrial operations.AXONEX has committed to provide up to HK$ 20,000,000 of capital to the joint venture in stages, subject to the achievement of defined business and technical milestones set out in the agreement. The funding will be released through four tranches over an expected 12–24-month period.STG will contribute technology, intellectual property, know-how, and ongoing technical support to the JV company, initially via a license of its core digital twin and drone flight control platforms, the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies” to Axonex Automation Limited.Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint stated: “This joint venture creates a focused vehicle to bring next-generation digital twin and autonomous drone capabilities from concept to commercial reality across Hong Kong and key overseas markets.”A representative of Synergy Technology Group Limited added: “Our collaboration with AXONEX will accelerate the real-world adoption of our digital twin and drone flight control technologies in critical infrastructure, smart city, and industrial applications, leveraging Hong Kong as a launchpad for global expansion.”Photo CaptionMr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint (Right) and Mr. Jiang Xiaotong, founder of STG (Left) signed the JV to establish Axonex Automation Limited focused on commercializing advanced digital twin and drone flight control technologies in Hong Kong and selected overseas markets.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Axonex Intelligence Limited, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.About Synergy Technology Group LimitedSynergy Technology Group Limited is a Hong Kong-based technology company specializing in advanced digital twin solutions and drone flight control systems, with applications across infrastructure monitoring, utilities, and smart city ecosystems. Founded by Jiang Xiaotong, an Associate Professor at Southeast University, Synergy Technology Group Limited operates under a license from Nanjing Zhishan Intelligent Technology Research Institute Co., Ltd for the “Zhishan No-Code Digital Twin Universal Platform and related drone inspection technologies”.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company’s filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月12日 - (亞太商訊 via SeaPRwire.com) - Mint Incorporation Limited（「Mint」或「集團」，納斯達克股票代碼：MIMI）─ 一家專注於人工智能與機械人技術，同時提供商業室內設計及裝修服務的香港本地企業，今日欣然宣布，其全資子公司 Axonex Intelligence Limited （「AXONEX」）已與互惠智科有限公司（「互惠智科」）訂立合資協議，共同成立Axonex Automation Limited（「合資企業」），一家總部位於香港，專注香港及特定海外市場將先進的數字孿生及無人機飛行控制技術商業化的新合資企業。根據合資協議，AXONEX將持有Axonex Automation Limited 80%的股權，而互惠智科將持有其餘20%。這合資協議將結合AXONEX的營運資源與國際業務能力，及互惠智科在數字孿生與無人機飛行控制系統領域的成熟技術，以推動在基礎設施檢測、公用事業、智慧城市及工業營運等領域的可規模化部署。AXONEX 已承諾按階段向合資企業投入最高達20,000,000港元的資金，具體金額將按協議所訂明的業務及技術里程碑的達成情況而擬定。相關資金預計將於12至24個月期間內分四期撥付。互惠智科將向合資企業提供技術、知識產權、專業技能及持續的技術支援，初期將向Axonex Automation Limited授權其「止善零代碼數字孿生通用平台」及無人機巡檢相關業務。Mint董事會主席兼行政總裁陳海龍先生表示：「是次與互惠智科的合資協議將創建一個平台，專注將新一代數字孿生及自動駕駛無人機技術，在香港及多個重要海外市場從概念階段推向商業應用。」互惠智科有限公司的代表補充道：「與AXONEX的合作將加速我們的數字孿生及無人機飛行控制技術在關鍵基礎設施、智慧城市及工業應用領域的實際落地，並以香港為起點，實現全球業務拓展。」圖片說明Mint董事會主席兼行政總裁陳海龍先生（右）與互惠智科創辦人姜曉彤先生（左）簽署合資協議，共同成立Axonex Automation Limited，專注香港及特定海外市場將先進的數字孿生及無人機飛行控制技術商業化。有關Mint Incorporation LimitedMint Incorporation Limited（納斯達克股票代碼：MIMI）是一家於納斯達克上市的香港本地企業，專注於人工智能、機械人技術及室內設計領域。透過其子公司 Axonex Intelligence Limited，公司為企業、地產、商場、政府機構等提供智能機械人與設施管理解決方案。Mint 同時營運 Matter International Limited，提供專業室內設計與裝修服務。秉持創新與實際應用並重的理念，Mint 致力於提升各行各業的效率、安全性與生活質素。有關互惠智科有限公司互惠智科有限公司是一家總部位於香港的科技企業，專門提供先進的數字孿生解決方案及無人機飛行控制系統，其應用領域涵蓋基礎設施監測、公共設施及智慧城市生態系統。由東南大學副教授姜曉彤創立，互惠智科有限公司獲南京止善智能科技研究院有限公司所授予的許可，營運「止善零代碼數字孿生通用平台」及「無人機巡檢」相關業務。前瞻性陳述本新聞稿中的某些陳述屬於前瞻性陳述。這些前瞻性陳述涉及已知和未知的風險和不確定性，並基於公司對可能影響其財務狀況、營運成果、業務策略和財務需求的未來事件的目前期望和預測。投資者可通過「大約」、 「相信 」、 「希望 」、 「期望 」、 「預期 」、 「估計 」、「項目 」、 「打算 」、 「計劃 」、 「將 」、 「將會 」、 「應該 」、 「可能 」或其他類似的詞語或短語識別這些前瞻性陳述。公司不承擔更新或修訂任何前瞻性陳述以反映隨後發生的事件或情況，或其期望的變化的公開義務，除非法律要求。儘管公司認為這些前瞻性陳述所表達的期望是合理的，但無法保證這些期望將會被證實正確，並提醒投資者實際結果可能與預期結果有顯著差異，並鼓勵投資者查閱可能影響其未來結果的其他因素，這些因素披露在公司向證券交易委員會提交的文件中。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com